Knowledge

The Breakthrough: Immunotherapy and the Race to Cure Cancer

Source đź“ť

27: 211:
When Graeber was considering writing a book about curing cancer using immunotherapy, he had approached his agent Susan Golomb who in turn sought the advice of her father, a retired oncologist. After being told not to bother, "it doesn't work", she had decided to support Graeber with his book anyway.
268:, Barbara Kiser called Graeber's book a "deft, detailed study of cancer immunotherapy" and included, "From the once-discredited pioneer William Coley to immunologist and Nobel laureate James P. Allison, they form a brilliant, driven, admirably stubborn group that Graeber brings vividly to life." For 280:, David A. Shaywitz found it "Engaging" and added "In Mr. Graeber's hands, the evolution of immuno-oncology is both captivating and heartbreaking." He went on to say, "We can't fail to see ourselves, our friends and our families in these stories." For the 274:, journalist and author Mimi Swartz stated that Graeber's book "artfully traces the history of old and new developments that may have — finally — resulted in an actual cure for the most dreaded of all diseases." In 212:
It was a challenging book to write, according to Graeber, because he had trouble coming up with gripping true tales that also represented the big picture. It took four years to research and to complete the book.
223:
is written for the lay reader and includes sections on immunology that have been written for a general audience. It examines the development of cancer immunotherapy, starting with
227:
work with toxins in the 1890s, moving on to the long hiatus of immunotherapy, and concluding with victory for the believers in the form of regulatory approval of
422: 286:, Douglas J. Johnston reviewed it as “Brilliantly rendered." and added, "pulls you into the narrative right off the hop and never lets go.” 183:. The book was written for the lay reader and includes sections on immunology written for a general audience. It was published by 449: 345:"A call for a rational future, 100 million years of European history, and the hidden horror of the dairy trade: Books in brief" 196: 532: 527: 165: 154: 395: 522: 232: 251:
were awarded the Nobel Prize in Physiology or Medicine in October 2018 for their work on cancer immunology.
298: 262:
was generally well received, including positive peer reviews. In a five-book review for the journal
319: 427: 276: 247:
T-cell therapies. The book was published shortly before James P. Allison and Tasuku Honjo from
475: 358: 240: 8: 454: 450:"A tough cell: Costly checkpoint inhibitors could prove pivotal to battle against cancer" 282: 362: 400: 376: 270: 184: 82: 423:"'The Breakthrough' and 'The Beautiful Cure' Review: Spurring the Body to Fight Back" 200: 149: 380: 366: 349: 263: 248: 188: 505: 180: 40: 371: 344: 26: 516: 224: 192: 69: 244: 124: 118: 114: 179:
is a non-fiction book written by American journalist and author
228: 236: 128: 297:
was shortlisted as the 2019 Medical Book of the Year by the
176:
The Breakthrough: Immunotherapy and the Race to Cure Cancer
514: 396:"Could Immunotherapy Offer a Cure for Cancer?" 25: 370: 447: 420: 317: 515: 476:"Alumnus Author Discusses Latest Book" 393: 342: 197:Nobel Prize in Physiology or Medicine 448:Johnston, Douglas J. (2019-01-26). 320:"Charles Graeber: The Breakthrough" 13: 14: 544: 497: 421:Shaywitz, David A. (2018-11-13). 468: 441: 414: 387: 336: 311: 1: 343:Kiser, Barbara (2018-10-31). 318:Lamberg, Lynne (2019-04-03). 304: 254: 206: 7: 394:Swartz, Mimi (2019-01-07). 299:British Medical Association 215: 10: 549: 372:10.1038/d41586-018-07186-3 289: 245:chimeric antigen receptor 160: 148: 137: 106: 98: 88: 78: 62: 54: 46: 36: 24: 533:Twelve (publisher) books 528:Books by Charles Graeber 428:The Wall Street Journal 277:The Wall Street Journal 47:Audio read by 16:Book by Charles Graeber 523:2018 non-fiction books 31:2018 hardcover edition 241:checkpoint inhibitors 455:Winnipeg Free Press 363:2018Natur.563...33K 283:Winnipeg Free Press 21: 480:Westminster School 401:The New York Times 271:The New York Times 199:for their work on 19: 201:cancer immunology 172: 171: 99:Publication place 94:November 13, 2018 20:The Breakthrough 540: 509: 508: 506:Official website 491: 490: 488: 487: 472: 466: 465: 463: 462: 445: 439: 438: 436: 435: 418: 412: 411: 409: 408: 391: 385: 384: 374: 340: 334: 333: 331: 330: 315: 295:The Breakthrough 260:The Breakthrough 249:Kyoto University 221:The Breakthrough 189:James P. Allison 168: 90:Publication date 29: 22: 18: 548: 547: 543: 542: 541: 539: 538: 537: 513: 512: 504: 503: 500: 495: 494: 485: 483: 474: 473: 469: 460: 458: 446: 442: 433: 431: 419: 415: 406: 404: 392: 388: 341: 337: 328: 326: 316: 312: 307: 292: 257: 225:William Coley's 218: 209: 181:Charles Graeber 166:twelvebooks.com 164: 143:(first edition) 133: 107:Media type 91: 74: 41:Charles Graeber 32: 17: 12: 11: 5: 546: 536: 535: 530: 525: 511: 510: 499: 498:External sites 496: 493: 492: 467: 440: 413: 386: 335: 309: 308: 306: 303: 291: 288: 256: 253: 217: 214: 208: 205: 170: 169: 162: 158: 157: 152: 146: 145: 139: 135: 134: 132: 131: 121: 110: 108: 104: 103: 100: 96: 95: 92: 89: 86: 85: 80: 76: 75: 73: 72: 66: 64: 60: 59: 56: 52: 51: 48: 44: 43: 38: 34: 33: 30: 15: 9: 6: 4: 3: 2: 545: 534: 531: 529: 526: 524: 521: 520: 518: 507: 502: 501: 481: 477: 471: 457: 456: 451: 444: 430: 429: 424: 417: 403: 402: 397: 390: 382: 378: 373: 368: 364: 360: 356: 352: 351: 346: 339: 325: 321: 314: 310: 302: 300: 296: 287: 285: 284: 279: 278: 273: 272: 267: 266: 261: 252: 250: 246: 242: 238: 234: 230: 226: 222: 213: 204: 202: 198: 195:won the 2018 194: 190: 186: 182: 178: 177: 167: 163: 159: 156: 155:9781455568505 153: 151: 147: 144: 140: 136: 130: 126: 122: 120: 116: 112: 111: 109: 105: 102:United States 101: 97: 93: 87: 84: 81: 77: 71: 68: 67: 65: 61: 57: 53: 49: 45: 42: 39: 35: 28: 23: 484:. Retrieved 482:. 2020-02-21 479: 470: 459:. Retrieved 453: 443: 432:. Retrieved 426: 416: 405:. Retrieved 399: 389: 357:(7729): 33. 354: 348: 338: 327:. Retrieved 323: 313: 294: 293: 281: 275: 269: 264: 259: 258: 220: 219: 210: 193:Tasuku Honjo 187:just before 175: 174: 173: 142: 50:Will Collyer 70:Non-fiction 517:Categories 486:2022-12-26 461:2022-12-26 434:2022-12-26 407:2022-12-26 329:2022-12-26 305:References 125:Audio book 255:Reception 207:Backstory 123:Digital: 119:Paperback 115:Hardcover 79:Publisher 381:53171456 324:nasw.org 216:Synopsis 55:Language 359:Bibcode 239:immune 161:Website 113:Print: 58:English 379:  350:Nature 290:Awards 265:Nature 235:, and 229:CTLA-4 185:Twelve 83:Twelve 63:Genres 37:Author 377:S2CID 237:PD-L1 138:Pages 129:eBook 243:and 233:PD-1 191:and 150:ISBN 141:320 367:doi 355:563 519:: 478:. 452:. 425:. 398:. 375:. 365:. 353:. 347:. 322:. 301:. 231:, 203:. 127:, 117:, 489:. 464:. 437:. 410:. 383:. 369:: 361:: 332:.

Index


Charles Graeber
Non-fiction
Twelve
Hardcover
Paperback
Audio book
eBook
ISBN
9781455568505
twelvebooks.com
Charles Graeber
Twelve
James P. Allison
Tasuku Honjo
Nobel Prize in Physiology or Medicine
cancer immunology
William Coley's
CTLA-4
PD-1
PD-L1
checkpoint inhibitors
chimeric antigen receptor
Kyoto University
Nature
The New York Times
The Wall Street Journal
Winnipeg Free Press
British Medical Association
"Charles Graeber: The Breakthrough"

Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.

↑